BOK Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

BOK Financial’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5	Closed	-$1.71K	–	1286
2024 Q4	$1.71K	Buy	5 +4	+400%	+$1.36K	﹤0.01%	1159
2024 Q3	$337	Hold	1	–	–	﹤0.01%	1270
2024 Q2	$273	Buy	+1	New	+$291	﹤0.01%	1136
2024 Q1	–	Sell	-1	Closed	-$322	–	1205
2023 Q4	$322	Buy	+1	New	+$313	﹤0.01%	1201
2023 Q3	–	Sell	-8	Closed	-$3.03K	–	1192
2023 Q2	$3.03K	Sell	8 -3	-27%	-$1.22K	﹤0.01%	1010
2023 Q1	$5.27K	Buy	+11	New	+$5.15K	﹤0.01%	1047
2016 Q3	–	Sell	-2,238	Closed	-$320K	–	883
2016 Q2	$320K	Sell	2,238 -2,983	-57%	-$425K	0.01%	702
2016 Q1	$714K	Buy	5,221 +91	+2%	+$11.9K	0.03%	498
2015 Q4	$711K	Sell	5,130 -1,890	-27%	-$262K	0.03%	499
2015 Q3	$943K	Buy	7,020 +2,627	+60%	+$378K	0.04%	430
2015 Q2	$662K	Buy	+4,393	New	+$628K	0.02%	534
2014 Q2	–	Sell	-1,764	Closed	-$226K	–	915
2014 Q1	$226K	Buy	+1,764	New	+$226K	0.01%	818

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BOK Financial's BIO Position: Q1 2025 in Review

BOK Financial sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 5 shares — an estimated $1.71K sold.

BOK Financial first reported a position in BIO in Q1 2014 and held it in 12 quarters. The position peaked at $943K in Q3 2015. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

BOK Financial reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
BOK Financial sold 5 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $1.71K.
BOK Financial first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 12 quarters.
BOK Financial's Bio-Rad Laboratories Class A position peaked at $943K in Q3 2015.
436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on BOK Financial's 13F filing for Q1 2025, filed 13 May 2025.